Figure 6.

Cas13a-based tool inhibits the formation of intracranial tumors. (A) Schematic of experimental grouping and processing of the orthotopic xenograft model. Oral administration of AZD4547 (50 mg/kg) was performed daily in the U87-F3-T3-AZD4547 group. (B and C) Bioluminescence imaging of tumor growth in animals. Signal intensities were quantified at days 7, 14, and 21 after implantation. n = 6 per group. ####p < 0.0001 versus the control group; ∗∗p < 0.01 and ∗∗∗∗p < 0.0001 versus the F3-T3 group. (D) Kaplan-Meier survival curves indicating the percentage survival of mice. ###p < 0.001 versus the control group; ∗p < 0.05 and ∗∗∗p < 0.001 versus the F3-T3 group; log rank test. (E) Graphic representation of weight of animals over time. n = 6 for each group. ####p < 0.0001 versus the control group; ∗∗∗∗p < 0.0001 versus the F3-T3 group. ns, p > 0.05. (F) Representative images of H&E staining of mouse cerebrum showing tumor volume. (G) Immunohistochemical (IHC) staining for Ki67 in the samples. Scale bar, 50 μm. (H) Quantification of Ki67 was performed using ImageJ software for each high-magnification view. n = 6 per group. Scale, 50 μm. ####p < 0.0001 versus the control group. ∗p < 0.05 and ∗∗∗∗p < 0.0001 versus the F3-T3 group